CRNX Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The c…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […] | ||
 Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026. | ||
 Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth. | ||
 Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued Crinetics Pharmaceuticals (CRNX) is in focus after reporting second quarter 2026 results that paired revenue of US$25.12 million with a net loss of US$120.86 million and a basic loss per share of US$1.14. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' share price has risen strongly over the past year, with a 30 day share price return of 98.34% and a 1 year total shareholder return of 186.46%, reflecting rising expectations after the Vertex acquisition... | ||
Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength | ||
 VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products. | ||
 Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call | ||
 Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic... | ||
Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high... | ||
 Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +7.32% and +69.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year. | ||
 Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target There are other reasons to pay attention to Viking Therapeutics. | ||
 Vertex was sole bidder in high-premium Crinetics acquisition Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction. | ||
Biotech IPO Gains Crush AI Listings With Standout 55% Return (Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam | ||
 Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […] | ||
 Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be. | ||
 Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? Vertex Pharmaceuticals recently announced its largest-ever acquisition. | ||